NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CollPlant Biotechnologies Ltd. (CLGN) Stock Analysis

CollPlant Biotechnologies Ltd. (CLGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CLGN

$3.60

+$0.19 (+5.51%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLGN with… →

CLGN Key Statistics

As of Sep 4, 2026
Trading
Open
$3.31
Previous Close
$3.41
Day's Range
2.99–3.91
52-Week Range
2.64–31.80
Volume
235.42K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.74
Valuation
Market Cap
$6.71M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
17.26
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.40
Financials (FY)
Revenue (FY)
$2.37M+360.39%
Net Income (FY)
−$11.49M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.89M
1-Year Return
+38.04%
Dividend and dates
Earnings Date
September 8, 2026estimated
Avg Volume
333.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CLGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+157.14%
2025−61.11%
2024−43.66%
2023−23.47%
2022−48.96%
2021+51.90%
2020+88.95%
2019+35.71%
2018−53.07%

As of September 4, 2026.

CLGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.37M−$11.49M−484.6%
2024$515.00K−$16.61M−3225.0%
2023$10.96M−$7.02M−64.0%
2022$299.00K−$16.93M−5660.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.37M$1.54M−$11.48M−$11.49M−484.6%
2024$515.00K−$1.11M−$17.25M−$16.61M−3225.0%
2023$10.96M$8.97M−$7.51M−$7.02M−64.0%
2022$299.00K−$101.00K−$17.10M−$16.93M−5660.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricCLGNBiotechnology medianvs median
P/S ratio17.2615.2613% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CollPlant Biotechnologies Ltd. (CLGN) carries a market capitalisation of $6.71M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 39 employees.

The most recent close on file for CLGN is $3.60, dated September 4, 2026. That is +$0.19 (+5.51%) against the previous close. The 52-week range on file runs from $2.64 to $31.80. The latest close sits 36.52% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.37M. That is +360.39% against the prior fiscal year, when revenue was $515.00K. The same year closed with a net loss of $11.49M. The reported profit margin is 0%. Trailing earnings per share are −10.4.

Across the 4 fiscal years on file, revenue moves from $299.00K in 2022 to $2.37M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 17.26. On price-to-sales that is 13.05% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.74. Annualized volatility over the trailing 8 years is 328.27%. The trailing one-year price return is +38.04%. Measured over 5 years, that is −27.42% a year compounded.

Growth & Income

The record shows no dividend for CLGN.

Across the complete calendar years on file, 2020 returned +88.95% and 2025 returned −61.11%. Of the 8 complete calendar years on file, 3 finished higher. So far in 2026 the price is +157.14%.

Peer Comparison

CollPlant Biotechnologies Ltd. (CLGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CollPlant Biotechnologies Ltd. CLGN $6.71M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CollPlant Biotechnologies Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Visit website →